Protocol Ledger

NCT06188741 · Phase II · RECRUITING

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Interventional Phase II clinical trial protocol NCT06188741 sponsored by University of Alabama at Birmingham in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-27 Enrollment: 200 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06188741
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)200 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06188741
Protocol FieldVerified Registry Value
NCT IdentifierNCT06188741
Consolidated Lead SponsorUniversity of Alabama at Birmingham
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment200 participants (ESTIMATED)
Registered Start Date2025-08-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI